Login | Forgot password?
June 27, 2017

In July 2006, BrainsGate initiated ImPACT-1: a pilot clinical study to assess the safety and efficacy of SPG stimulation for treatment of acute ischemic stroke in a 24 hour window from stroke onset. ImPACT-1 completed its recruitment in late 2008, haveing enrolled 98 patients. Results from ImPACT-1 were published in several conferences during 2008 (see publications).

Following the promising results of ImpACT-1, BriansGate has launched ImpACT-24: a randomized, double-blind, sham-controlled study to assess the safety and efficacy of SPG stimulation in a 24 hour window from symptom onset. ImpACT-24 is a multi-national trial with centers in America, Europe and Asia, and is currently enrolling patients. The study was concluded in 2011 providing strong support to the ImpACT-1 outcomes, leading the way to the ImpACT-24B pivotal trial that is currently enrolling patients.

For more information about ImpACT-24 or if you want to join the study please contact us.

July 16, 2014
ImpACT24 Interim Results
The Data Safety Monitoring Board (the "DSMB") for BrainsGate's study examined the interim results and deterimined the results support the continuation of the study > full story
January 1, 1970
> full story